ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2

Endocrine-Related Cancer

Volumn 15, Issue 4, 2008, Pages 985-1002

  Pancholi, Sunil ^a   Lykkesfeldt, Anne E ^b   Hilmi, Caroline ^a   Banerjee, Susana ^a   Leary, Alexandra ^a   Drury, Suzanne ^a   Johnston, Stephen ^c   Dowsett, Mitch ^a   Martin, Lesley Ann ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BENZOTHIAZOLYL)THIOMETHYL 4 HYDROXY 3 METHOXYBENZYLIDENECYANOACETAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FULVESTRANT; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN RPS6KA2; SMALL INTERFERING RNA; TAMOXIFEN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; CELLULAR DISTRIBUTION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; BLOTTING, WESTERN; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TAMOXIFEN; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 58249105933     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-07-0240     Document Type: Article

References (57)

1. Ali S & Coombes RC 2002 Endocrine-responsive breast cancer and strategies for combating resistance. Nature Reviews. Cancer 2 101-112.
2. Bates NP & Hurst HC 1997 An intron 1 enhancer element mediates oestrogen-induced suppression of ERBB2 expression. Oncogene 15 473-481.
3. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM & Osborne CK 1992 Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Research and Treatment 24 85-95.
4. Bonni A, Brunet A, West AE, Datta SR, Takasu MA & Greenberg ME 1999 Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286 1358-1362.
5. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Ryden S & Sigurdsson H 1994 ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Letters 81 137-144.
6. Bunone G, Briand PA, Miksicek RJ & Picard D 1996 Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO Journal 15 2174-2183.
7. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S & Nakshatri H 2001 Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. Journal of Biological Chemistry 276 9817-9824.
8. Cancer Trialists' Collaborative Group 1998 Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 1451-1467.
9. Chan CM, Martin L-A, Johnston SR, Ali S & Dowsett M 2002 Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. Journal of Steroid Biochemistry and Molecular Biology 81 333-341.
10. Chung YL, Sheu ML, Yang SC, Lin CH & Yen SH 2002 Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. International Journal of Cancer 97 306-312.
11. Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM & El-Ashry D 2006 Activation of mitogen-activated protein kinase in estrogen receptor α-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor α-negative human breast tumors. Cancer Research 66 3903-3911.
12. de Cremoux P, Tran-Perennou C, Brockdorff BL, Boudou E, Brunner N, Magdelenat H & Lykkesfeldt AE 2003 Validation of real-time RT-PCR for analysis of human breast cancer cell lines resistant or sensitive to treatment with antiestrogens. Endocrine-Related Cancer 10 409-418.
13. Cui Y, Zhang M, Pestell R, Curran EM, Welshons WV & Fuqua SA 2004 Phosphorylation of estrogen receptor alpha blocks its acetylation and regulates estrogen sensitivity. Cancer Research 64 9199-9208.
14. DeNardo DG, Kim HT, Hilsenbeck S, Cuba V, Tsimelzon A & Brown PH 2005 Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: identification of estrogen-induced/ activator protein- 1 -dependent genes. Molecular Endocrinology 19 362-378.
15. Dowsett M 2001 Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocrine-Related Cancer 8 191-195.
16. Dowsett M, Goss PE, Powles TJ, Hutchinson G, Brodie AM, Jeffcoate SL & Coombes RC 1987 Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Research 47 1957-1961.
17. Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M, Ebbs S, Gui G, Sacks N & Smith I 2001 HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Research 61 8452-8458.
18. Fan P, Wang J, Santen RJ & Yue W 2007 Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Research 67 1352-1360.
19. Font de Mora J & Brown M 2000 AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Molecular and Cellular Biology 20 5041-5047.
20. Frogne T, Jepsen JS, Larsen SS, Fog CK, Brockdorff BL & Lykkesfeldt AE 2005 Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth. Endocrine-Related Cancer 12 599-614.
21. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK & Dowsett M 2005 Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. Journal of Clinical Oncology 23 2469-2476.
22. Herynk MH, Parra I, Cui Y, Beyer A, Wu MF, Hilsenbeck SG & Fuqua SA 2007 Association between the estrogen receptor α A908G mutation and outcomes in invasive breast cancer. Clinical Cancer Research 13 3235-3243.
23. Horner-Glister E, Maleki-Dizaji M, Guerin CJ, Johnson SM, Styles J & White IN 2005 Irifluence of oestradiol and tamoxifen on oestrogen receptors-alpha and -beta protein degradation and non-genomic signalling pathways in uterine and breast carcinoma cells. Journal of Molecular Endocrinology 35 421-432.
24. Hutcheson IR, KnowIden JM, Madden TA, Barrow D, Gee JM, Wakeling AE & Nicholson RI 2003 Oestrogen receptor-mediated modulation of the EGFR/ MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Research and Treatment 81 81-93.
25. Hynes NE & Lane HA 2005 ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews. Cancer 5 341-354.
26. Jeng MH, Shupnik MA, Bender TP, Westin EH, Bandyopadhyay D, Kumar R, Masamura S & Santen RJ 1998 Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 139 4164-4174.
27. Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J & Lannigan DA 1998 pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Molecular and Cellular Biology 18 1978-1984.
28. Johnston SR, Haynes BP, Smith IE, Jarman M, Sacks NP, Ebbs SR & Dowsett M 1993 Acquired tamoxifen resistance in human breast cancer and reduced intratumoral drug concentration. Lancet 342 1521-1522.
29. Jordan NJ, Gee JMW, Barrow D, Wakeling AE & Nicholson RI 2004 Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Research and Treatment 87 167-180.
30. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida. E, Kawashima H et al. 1995 Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270 1491-1494.
31. Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A & Bartlett JM 2005 AKT activation predicts outcome in breast cancer patients treated with tamoxifen. Journal of Pathology 207 139-146.
32. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE & Nicholson RI 2003 Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144 1023-1044.
33. Kumar R, Mandal M, Lipton A, Harvey H & Thompson CB 1996 Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. Clinical Cancer Research 2 1215-1219.
34. Kumar R, Wang RA, Mazumdar A, Talukder AH, Mandal M, Yang Z, Bagheri-Yarmand R, Sabin A, Hortobagyi G, Adam L et al. 2002 A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature 418 654-657.
35. Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT & Arteaga CL 2000 Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Research 60 5887-5894.
36. Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, Harvey H, Demers L & Lipton A 1995 Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. Journal of Clinical Oncology 13 1129-1135.
37. Long BJ, Jelovac D, Thiantanawat A & Brodie AM 2002 The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Clinical Cancer Research 8 2378-2388.
38. Lykkesfeldt AE, Madsen MW & Briand P 1994 Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR- 1. Cancer Research 54 1587-1595.
39. Madsen MW, Reiter BE, Larsen SS, Briand P & Lykkesfeldt AE 1997 Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells. Cancer Research 57 585-589.
40. Martin L-A, Farmer I, Johnston SR, Ali S, Marshall C & Dowsett M 2003 Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. Journal of Biological Chemistry 278 30458-30468.
41. Masamura. S, Santner SJ, Heitjan DF & Santen RJ 1995 Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. Journal of Clinical Endocrinology and Metabolism 80 2918-2925.
42. Massarweh S & Schiff R 2007 Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clinical Cancer Research 13 1950-1954.
43. Metivier R, Penot G, Hubner MR, Reid G, Brand H, Kos M & Gannon F 2003 Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115 751-763.
44. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E & Auricchio F 1996 Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO Journal 15 1292-1300.
45. Nakajima T, Fukamizu A, Takahashi J, Gage FH, Fisher T, Blenis J & Montminy MR 1996 The signal-dependent coactivator CBP is a nuclear target for pp90RSK. Cell 86 465-474.
46. Newman SP, Bates NP, Vernimmen D, Parker MG & Hurst HC 2000 Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Oncogene 19 490-497.
47. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG & El-Ashry D 2001 Hyperactivation of MAPK induces loss of ERa expression in breast cancer cells. Molecular Endocrinology 15 1344-1359.
48. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM & Schiff R 2003 Role of the estrogen receptor coactivator AIB 1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. Journal of the National Cancer Institute 95 353-361.
49. Perissi V, Menini N, Cottone E, Capello D, Sacco M, Montaldo F & De Bortoti M 2000 AP-2 transcription factors in the regulation of ERBB2 gene transcription by oestrogen. Oncogene 19 280-288.
50. Shang Y, Hu X, DiRenzo J, Lazar MA & Brown M 2000 Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103 843-852.
51. Shim WS, Conaway M, Masamura S, Yue W, Wang JP, Kumar R & Santen RJ 2000 Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 141 396-405.
52. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H & Schiff R 2004 Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu crosstalk in ER/HER2-positive breast cancer. Journal of the National Cancer Institute 96 926-935.
53. Song RX, Barnes CJ, Zhang Z, Bao Y, Kumar R & Santen RJ 2004 The role of She and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. PNAS 101 2076-2081.
54. Tan Y, Ruan H, Demeter MR & Comb MJ 1999 p90(RSK) blocks bad-mediated cell death via a protein kinase C-dependent pathway. Journal of Biological Chemistry 274 34859-34867.
55. Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, Paulazzo G, Lyass L, Trusk P, Hill J et al. 2006 A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. PNAS 103 7795-7800.
56. Yang Z, Barnes CJ & Kumar R 2004 Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. Clinical Cancer Research 10 3621-3628.
57. Zha J, Harada H, Yang E, Jockel J & Korsmeyer SJ 1996 Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87 619-628.